Opportunistic screening
Intervention3 papers2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
Funders: Center for Innovative Medicine and 3 more
- Human trial1
- Humans1
Outcomes
2Population reach
downin humans1
1 study
Population reach
downin humans1
Opportunistic screening decreases population reach in humans (25.3% vs. 42.2%).
Human trial
Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 4 Aug 2026
Screening participation
upin humans1
1 study
Screening participation
upin humans1
Opportunistic screening increases screening participation in humans (61.4% vs. 46.3%).
Human trial
Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 4 Aug 2026
Funding
National Heart, Lung, and Blood InstituteUS$670.2k1 grant since 2023